Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Chemopreventive agent 3,3'-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases.

Li Y, Li X, Guo B.

Cancer Res. 2010 Jan 15;70(2):646-54. doi: 10.1158/0008-5472.CAN-09-1924. Epub 2010 Jan 12.

2.

Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.

Gibbs A, Schwartzman J, Deng V, Alumkal J.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16663-8. doi: 10.1073/pnas.0908908106. Epub 2009 Sep 15.

3.

The many roles of histone deacetylases in development and physiology: implications for disease and therapy.

Haberland M, Montgomery RL, Olson EN.

Nat Rev Genet. 2009 Jan;10(1):32-42. doi: 10.1038/nrg2485. Review.

4.

Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane.

Azarenko O, Okouneva T, Singletary KW, Jordan MA, Wilson L.

Carcinogenesis. 2008 Dec;29(12):2360-8. doi: 10.1093/carcin/bgn241. Epub 2008 Oct 23.

5.

The aggresome pathway as a target for therapy in hematologic malignancies.

Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, Sakamoto KM.

Mol Genet Metab. 2008 Jul;94(3):283-6. doi: 10.1016/j.ymgme.2008.03.012. Epub 2008 May 9. Review. Erratum in: Mol Genet Metab.2009 Jun;97(2):164.

6.

Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation.

Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM.

Cancer Res. 2008 Apr 15;68(8):2557-60. doi: 10.1158/0008-5472.CAN-07-5989. Review. Erratum in: Cancer Res. 2009 May 1;69(9):4092.

7.

Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

Bruserud Ø, Stapnes C, Ersvaer E, Gjertsen BT, Ryningen A.

Curr Pharm Biotechnol. 2007 Dec;8(6):388-400. Review.

PMID:
18289048
8.

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.

Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G.

Br J Cancer. 2008 Feb 12;98(3):604-10. doi: 10.1038/sj.bjc.6604199. Epub 2008 Jan 22.

9.

Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.

Mol Cancer Ther. 2007 Sep;6(9):2525-34.

10.

HDAC3 overexpression and colon cancer cell proliferation and differentiation.

Spurling CC, Godman CA, Noonan EJ, Rasmussen TP, Rosenberg DW, Giardina C.

Mol Carcinog. 2008 Feb;47(2):137-47.

PMID:
17849419
11.

Expression profile of class I histone deacetylases in human cancer tissues.

Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F, Basaki Y, Ono M, Kuwano M, Tanaka M, Tsuneyoshi M.

Oncol Rep. 2007 Oct;18(4):769-74.

PMID:
17786334
12.

Histone deacetylase inhibitors: molecular mechanisms of action.

Xu WS, Parmigiani RB, Marks PA.

Oncogene. 2007 Aug 13;26(37):5541-52. Review.

PMID:
17694093
13.

HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination.

Boyault C, Sadoul K, Pabion M, Khochbin S.

Oncogene. 2007 Aug 13;26(37):5468-76. Review.

PMID:
17694087
14.
15.

Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line.

Herman-Antosiewicz A, Xiao H, Lew KL, Singh SV.

Mol Cancer Ther. 2007 May;6(5):1673-81.

16.

Histone deacetylase inhibitors: signalling towards p21cip1/waf1.

Ocker M, Schneider-Stock R.

Int J Biochem Cell Biol. 2007;39(7-8):1367-74. Epub 2007 Mar 7. Review.

PMID:
17412634
17.

Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis.

Higdon JV, Delage B, Williams DE, Dashwood RH.

Pharmacol Res. 2007 Mar;55(3):224-36. Epub 2007 Jan 25. Review.

18.

Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.

Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E.

Exp Biol Med (Maywood). 2007 Feb;232(2):227-34.

19.

Quantitative measurement of sulforaphane, iberin and their mercapturic acid pathway metabolites in human plasma and urine using liquid chromatography-tandem electrospray ionisation mass spectrometry.

Al Janobi AA, Mithen RF, Gasper AV, Shaw PN, Middleton RJ, Ortori CA, Barrett DA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Dec 5;844(2):223-34. Epub 2006 Aug 23.

PMID:
16931178
20.

Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells.

Herman-Antosiewicz A, Johnson DE, Singh SV.

Cancer Res. 2006 Jun 1;66(11):5828-35.

Supplemental Content

Support Center